The Motley Fool
02 Nov 2026, 09:13 UTC · 1h ago
ResMed: 3 Key Takeaways for Long-Term Investors
Impact · against what's priced in
ResMed shows positive operational momentum and a strategic hedge against GLP-1 fears, but the news is primarily incremental. The reported revenue growth, margin expansion, and divestiture of noncore assets are consistent with standard execution for a market leader.
- RMD+0.40
No priced-in read yet
- In context
The company is seeing higher CPAP initiation and retention rates among GLP-1 users, countering the narrative that weight-loss drugs would cannibalize sleep apnea therapy. Additionally, 7% core revenue growth and expanding gross margins suggest strong operational leverage.
Read from the article alone
